<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We report the first large prospective study of children with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and juvenile myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>) treated in a uniform fashion on Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group protocol 2891 </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Ninety children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>, various forms of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) with antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were treated with a five-drug induction regimen (standard or intensive timing) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients achieving remission were allocated to allogeneic bone marrow transplantation (BMT) if a matched family donor was available </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> other patients were randomized between autologous BMT and aggressive nonmyeloablative chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Results were compared with patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) or RA-excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) exhibited high induction failure rates and overall remission of 58% and 48%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Remission rates for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) (69%) or antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (81%) were similar to de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (77%) </plain></SENT>
<SENT sid="7" pm="."><plain>Actuarial survival rates at 6 years were as follows: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e>, 31% +/- 26%; RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 29% +/- 16%; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>, 30% +/- 18%; antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 50% +/- 25%; and de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 45% +/- 3% </plain></SENT>
<SENT sid="8" pm="."><plain>For patients achieving remission, long-term survivors were found in those receiving either allogeneic BMT or chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>The presence of <z:mp ids='MP_0004026'>monosomy</z:mp> 7 had no additional adverse effect on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Childhood subtypes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> represent distinct entities with distinct clinical outcomes </plain></SENT>
<SENT sid="11" pm="."><plain>Children with a history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who present with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> do well with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-type therapy </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with RA or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> respond poorly to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> induction therapy </plain></SENT>
<SENT sid="13" pm="."><plain>The optimum treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JMML</z:e> remains unknown </plain></SENT>
</text></document>